Lifecore Biomedical
LFCR
82 hedge funds and large institutions have $121M invested in Lifecore Biomedical in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 28 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
17% more call options, than puts
Call options by funds: $124K | Put options by funds: $106K
8.67% less ownership
Funds ownership: 83.41% → 74.74% (-8.7%)
12% less funds holding
Funds holding: 93 → 82 (-11)
19% less capital invested
Capital invested by funds: $149M → $121M (-$27.9M)
39% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 28
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
+$5.77M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.65M |
| 3 |
WC
Wynnefield Capital
New York
|
+$2.57M |
| 4 |
Morgan Stanley
New York
|
+$1.28M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$9.58M |
| 2 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
-$5.03M |
| 3 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$3.91M |
| 4 |
PRCP
Pacific Ridge Capital Partners
Lake Oswego,
Oregon
|
-$2.7M |
| 5 |
ICM
ISZO Capital Management
New York
|
-$2.42M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
101
Legato Capital Management
San Francisco,
California
| – | -$99.5K | -15,354 | Closed |
|
|
AG
102
Algert Global
San Francisco,
California
| – | -$79K | -12,206 | Closed |
|
|
JF
103
Jump Financial
Chicago,
Illinois
| – | -$79.1K | -12,200 | Closed |
|
104
Allspring Global Investments
Charlotte,
North Carolina
| – | -$46.1K | -7,115 | Closed |
|
|
CSS
105
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$36.4K | -5,613 | Closed |
|
106
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$24K | -3,630 | Closed |
|
|
PMEF
107
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$6.03K | -930 | Closed |
|
|
ACM
108
Aquatic Capital Management
Chicago,
Illinois
| – | -$6K | -900 | Closed |
|
|
EI
109
Ellevest Inc
New York
| – | -$1.91K | -294 | Closed |
|
|
CS
110
Credit Suisse
Zurich,
Switzerland
| – | -$6 | -1 | Closed |
|
LFCR Hedge Fund Activity: Q1 2023 in Review
82 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2023, worth a combined $121M — down 19% from $149M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of LFCR and 17 opened new positions — a net loss of 11 holders — while 18 trimmed existing stakes and 26 added.
The largest buyer was Greenhaven Road Investment Management, opening a new position worth an estimated $5.77M. The largest seller was Dimensional Fund Advisors, cutting an estimated $9.58M.
- 82 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2023, down from 93 in Q4 2022.
- Funds reported $121M of Lifecore Biomedical stock for Q1 2023, down 19% quarter-over-quarter.
- 17 funds opened new Lifecore Biomedical positions in Q1 2023 and 28 closed out, a net change of -11 holders.
- The largest Lifecore Biomedical buyer in Q1 2023 was Greenhaven Road Investment Management, an estimated $5.77M added.
- The largest Lifecore Biomedical seller in Q1 2023 was Dimensional Fund Advisors, an estimated $9.58M sold.
Based on aggregated 13F filings for Q1 2023.